Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) stock fell -4.32% on Monday to $1.33 against a previous-day closing price of $1.39. With 0.78 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.83 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $1.3700 whereas the lowest price it dropped to was $1.3300. The 52-week range on ZYNE shows that it touched its highest point at $1.40 and its lowest point at $0.25 during that stretch. It currently has a 1-year price target of $1.25. Beta for the stock currently stands at 1.32.
Price Performance and Earnings:
Three-month performance surged to 303.03% while six-month performance rose 202.27%. The stock gained 19.82% in the past year, while it has gained 150.94% so far this year. A look at the trailing 12-month EPS for ZYNE yields -0.80 with Next year EPS estimates of -0.63. For the next quarter, that number is 0.09. This implies an EPS growth rate of 13.60% for this year and 25.00% for next year.
Float and Shares Shorts:
At present, 53.94 million ZYNE shares are outstanding with a float of 50.24 million shares on hand for trading. On Aug 30, 2023, short shares totaled 0.24 million, which was 0.45% higher than short shares on Jul 30, 2023. In addition to Mr. Armando Anido MBA as the firm’s Chairman & CEO, Ms. Terri B. Sebree serves as its Pres.
Through their ownership of 12.13% of ZYNE’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.49% of ZYNE, in contrast to 5.51% held by mutual funds. Shares owned by individuals account for 13.94%. As the largest shareholder in ZYNE with 8.21% of the stake, Beryl Capital Management LLC holds 4,426,381 shares worth 4,426,381. A second-largest stockholder of ZYNE, The Vanguard Group, Inc., holds 2,163,437 shares, controlling over 4.01% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in ZYNE, holding 740,524 shares or 1.37% stake. With a 2.82% stake in ZYNE, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 1,521,801 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.20% of ZYNE stock, is the second-largest Mutual Fund holder. It holds 647,755 shares valued at 0.86 million. Fidelity Extended Market Index Fu holds 0.44% of the stake in ZYNE, owning 238,972 shares worth 0.32 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, ZYNE reported revenue of $0.00 and operating income of -$9.17M. The EBITDA in the recently reported quarter was -$8.34M and diluted EPS was -$0.24.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZYNE since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ZYNE analysts setting a high price target of $1.40 and a low target of $1.11, the average target price over the next 12 months is $1.26. Based on these targets, ZYNE could surge 5.26% to reach the target high and fall by -16.54% to reach the target low. Reaching the average price target will result in a decline of -5.26% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded ZYNE stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 21 while that of sell transactions has risen to 21 over the past year. The total number of shares bought during that period was 1,433,510 while 171,705 shares were sold.